X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IGT-427 is a bispecific antibody that potently blocks VEGF and activates Tie-2. Variants of IGT-427 had long intravitreal half-lives, suggesting potential for a less frequently administered and highly efficacious treatment for diabetic macular edema and wet AMA.
Lead Product(s): IGT-427
Therapeutic Area: Ophthalmology Product Name: IGT-427
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Ingenia Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Under terms of the agreement, the collaboration between Ocular Therapeutix and Mosaic focuses on the discovery and development of novel complement inhibitors with extended duration of activity.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ocular Therapeutix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
